These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31422649)

  • 21. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
    Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
    Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
    Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy.
    Kajinami K; Ozaki A; Tajima Y; Yamashita S; Arai H; Teramoto T
    J Atheroscler Thromb; 2019 May; 26(5):408-431. PubMed ID: 30369517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    Olsson AG; McTaggart F; Raza A
    Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention.
    Kim J; Park KT; Jang MJ; Park TK; Lee JM; Yang JH; Song YB; Choi SH; Gwon HC; Lee SH; Hong KP; Hahn JY
    J Am Heart Assoc; 2018 Nov; 7(21):e009517. PubMed ID: 30376751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
    Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
    Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and meta-analysis on the therapeutic equivalence of statins.
    Weng TC; Yang YH; Lin SJ; Tai SH
    J Clin Pharm Ther; 2010 Apr; 35(2):139-51. PubMed ID: 20456733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
    Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of rosuvastatin on low-density lipoprotein cholesterol and plasma lipids in Asian patients with hypercholesterolemia.
    Tan AT; Low LP; Lim CH; Tan CE
    J Atheroscler Thromb; 2009 Aug; 16(4):509-16. PubMed ID: 19729865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl.
    Piao ZH; Jin L; Kim JH; Ahn Y; Kim YJ; Cho MC; Kim CJ; Kim HS; Liu B; Jeong MH;
    Am J Cardiol; 2017 Jul; 120(2):174-180. PubMed ID: 28532771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.
    Barge-Caballero G; Barge-Caballero E; Marzoa-Rivas R; Paniagua-Martín MJ; Barrio-Rodríguez A; Naya-Leira C; Blanco-Canosa P; Grille-Cancela Z; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Transpl Int; 2015 Sep; 28(9):1034-41. PubMed ID: 25864881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.
    Catapano AL; Lee LV; Louie MJ; Thompson D; Bergeron J; Krempf M
    Sci Rep; 2017 Apr; 7():45788. PubMed ID: 28374849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.